{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:44Z","timestamp":1792783124525,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research start-up funds for high-level talents of Nanjing University","id":[{"id":"https:\/\/ror.org\/01rxvg760","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Research Program of Qilu Institute of Technology","award":["QIT25TP001"],"award-info":[{"award-number":["QIT25TP001"]}],"id":[{"id":"https:\/\/ror.org\/02g8mnh88","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The escalating crisis of antimicrobial resistance (AMR) necessitates the urgent development of alternatives to traditional antibiotics. Bacteriophage (phage) therapy, which utilizes viruses that specifically infect and lyse bacteria, has re-emerged as a promising therapeutic strategy. This review comprehensively examines the current landscape, beginning with the modern, genome-based classification of phages and detailing their key therapeutic advantages, including high specificity, self-amplification, and biofilm-penetrating capability. We explore advanced biotechnological applications such as genetic engineering of phages, the use of phage-derived proteins, and synergistic phage-antibiotic combinations (PAS). The translational workflow from phage sourcing and biobanking to characterization, formulation, and clinical delivery is critically analyzed, alongside major therapeutic areas like chronic wounds and pulmonary infections. Despite promising clinical evidence from compassionate use and trials, significant scientific, regulatory, and commercial hurdles remain. The integration of synthetic biology and artificial intelligence is poised to overcome these challenges, steering phage therapy toward becoming a precise and adaptable component of the modern antimicrobial arsenal.<\/jats:p>","DOI":"10.1007\/s11033-026-12537-9","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:16:11Z","timestamp":1785842171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phage as a prospective arsenal against superbugs"],"prefix":"10.1007","volume":"53","author":[{"given":"Lejia","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon Shui Yee","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"10325","key":"12537_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Collaborators","year":"2022","unstructured":"Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399(10325):629\u2013655","journal-title":"Lancet"},{"issue":"6","key":"12537_CR2","doi-asserted-by":"publisher","first-page":"107640","DOI":"10.1016\/j.ijantimicag.2025.107640","volume":"66","author":"RR Patel","year":"2025","unstructured":"Patel RR et al (2025) Overcoming antimicrobial resistance: Phage therapy as a promising solution to combat ESKAPE pathogens. Int J Antimicrob Agents 66(6):107640","journal-title":"Int J Antimicrob Agents"},{"key":"12537_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3389\/fmicb.2017.00981","volume":"8","author":"ST Abedon","year":"2017","unstructured":"Abedon ST et al (2017) Editorial: Phage Therapy: Past, Present and Future. Front Microbiol 8:981","journal-title":"Front Microbiol"},{"issue":"3","key":"12537_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","volume":"8","author":"DM Lin","year":"2017","unstructured":"Lin DM, Koskella B, Lin HC (2017) Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 8(3):162\u2013173","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"6","key":"12537_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/femsre\/fuaa017","volume":"44","author":"DP Pires","year":"2020","unstructured":"Pires DP et al (2020) Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev 44(6):684\u2013700","journal-title":"FEMS Microbiol Rev"},{"issue":"6","key":"12537_CR6","doi-asserted-by":"publisher","first-page":"107612","DOI":"10.1016\/j.ijantimicag.2025.107612","volume":"66","author":"H K\u00f6nig","year":"2025","unstructured":"K\u00f6nig H (2025) The prospect of approved and commercially available phage therapeutics. Int J Antimicrob Agents 66(6):107612","journal-title":"Int J Antimicrob Agents"},{"key":"12537_CR7","volume-title":"Bacteriophages - Perspectives and Future","author":"E Orlova","year":"2019","unstructured":"Orlova E, White H(2019) Bacteriophages: Their Structural Organisation and Function. In: Savva R (ed) Bacteriophages - Perspectives and Future. Intech Open, London"},{"issue":"3","key":"12537_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrmicro.2016.177","volume":"15","author":"P Simmonds","year":"2017","unstructured":"Simmonds P et al (2017) Consensus statement: Virus taxonomy in the age of metagenomics. Nat Rev Microbiol 15(3):161\u2013168","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"12537_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41579-019-0311-5","volume":"18","author":"MB Dion","year":"2020","unstructured":"Dion MB, Oechslin F, Moineau S (2020) Phage diversity, genomics and phylogeny. Nat Rev Microbiol 18(3):125\u2013138","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"12537_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00705-022-05694-2","volume":"168","author":"D Turner","year":"2023","unstructured":"Turner D et al (2023) Abolishment of morphology-based taxa and change to binomial species names: 2022 taxonomy update of the ICTV bacterial viruses subcommittee. Arch Virol 168(2):74","journal-title":"Arch Virol"},{"key":"12537_CR11","doi-asserted-by":"publisher","first-page":"1032186","DOI":"10.3389\/fmicb.2022.1032186","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y et al (2022) Phage family classification under Caudoviricetes: A review of current tools using the latest ICTV classification framework. Front Microbiol 13:1032186","journal-title":"Front Microbiol"},{"key":"12537_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0065-2164(10)70007-1","volume":"70","author":"P Hyman","year":"2010","unstructured":"Hyman P, Abedon ST (2010) Bacteriophage host range and bacterial resistance. Adv Appl Microbiol 70:217\u2013248","journal-title":"Adv Appl Microbiol"},{"key":"12537_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1146\/annurev.bi.58.070189.004405","volume":"58","author":"A Landy","year":"1989","unstructured":"Landy A (1989) Dynamic, structural, and regulatory aspects of lambda site-specific recombination. Annu Rev Biochem 58:913\u2013949","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"12537_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4161\/bact.1.2.15845","volume":"1","author":"ST Abedon","year":"2011","unstructured":"Abedon ST et al (2011) Phage treatment of human infections. Bacteriophage 1(2):66\u201385","journal-title":"Bacteriophage"},{"issue":"3","key":"12537_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1128\/MMBR.68.3.560-602.2004","volume":"68","author":"H Brussow","year":"2004","unstructured":"Brussow H, Canchaya C, Hardt WD (2004) Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol Mol Biol Rev 68(3):560\u2013602","journal-title":"Microbiol Mol Biol Rev"},{"issue":"5","key":"12537_CR16","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s00253-015-7247-0","volume":"100","author":"DP Pires","year":"2016","unstructured":"Pires DP et al (2016) Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol 100(5):2141\u20132151","journal-title":"Appl Microbiol Biotechnol"},{"issue":"1","key":"12537_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13099-023-00550-3","volume":"15","author":"H Raeisi","year":"2023","unstructured":"Raeisi H et al (2023) Emerging applications of phage therapy and fecal virome transplantation for treatment of Clostridioides difficile infection: challenges and perspectives. Gut Pathog 15(1):21","journal-title":"Gut Pathog"},{"issue":"3","key":"12537_CR18","doi-asserted-by":"publisher","first-page":"e0207121","DOI":"10.1128\/aac.02071-21","volume":"66","author":"GA Suh","year":"2022","unstructured":"Suh GA et al (2022) Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrob Agents Chemother 66(3):e0207121","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"12537_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.12793\/tcp.2023.31.e17","volume":"31","author":"D Chae","year":"2023","unstructured":"Chae D (2023) Phage-host-immune system dynamics in bacteriophage therapy: basic principles and mathematical models. Transl Clin Pharmacol 31(4):167\u2013190","journal-title":"Transl Clin Pharmacol"},{"issue":"27","key":"12537_CR20","doi-asserted-by":"publisher","first-page":"11197","DOI":"10.1073\/pnas.0704624104","volume":"104","author":"TK Lu","year":"2007","unstructured":"Lu TK, Collins JJ (2007) Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A 104(27):11197\u201311202","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"12537_CR21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick RM et al (2019) Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 25(5):730\u2013733","journal-title":"Nat Med"},{"issue":"1","key":"12537_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4161\/bact.18778","volume":"2","author":"LJ Marinelli","year":"2012","unstructured":"Marinelli LJ, Hatfull GF, Piuri M, Recombineering (2012) A powerful tool for modification of bacteriophage genomes. Bacteriophage 2(1):5\u201314","journal-title":"Bacteriophage"},{"issue":"12","key":"12537_CR23","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/s41564-022-01258-x","volume":"7","author":"BA Adler","year":"2022","unstructured":"Adler BA et al (2022) Broad-spectrum CRISPR-Cas13a enables efficient phage genome editing. Nat Microbiol 7(12):1967\u20131979","journal-title":"Nat Microbiol"},{"issue":"26","key":"12537_CR24","doi-asserted-by":"publisher","first-page":"15440","DOI":"10.1073\/pnas.2237126100","volume":"100","author":"HO Smith","year":"2003","unstructured":"Smith HO et al (2003) Generating a synthetic genome by whole genome assembly: phiX174 bacteriophage from synthetic oligonucleotides. Proc Natl Acad Sci U S A 100(26):15440\u201315445","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"12537_CR25","doi-asserted-by":"publisher","first-page":"8919","DOI":"10.1080\/10408398.2022.2059442","volume":"63","author":"C Lee","year":"2023","unstructured":"Lee C, Kim H, Ryu S (2023) Bacteriophage and endolysin engineering for biocontrol of food pathogens\/pathogens in the food: recent advances and future trends. Crit Rev Food Sci Nutr 63(27):8919\u20138938","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"4","key":"12537_CR26","doi-asserted-by":"publisher","first-page":"e01379","DOI":"10.1128\/mBio.01379-14","volume":"5","author":"Y Briers","year":"2014","unstructured":"Briers Y et al (2014) Engineered endolysin-based Artilysins to combat multidrug-resistant gram-negative pathogens. mBio 5(4):e01379\u2013e01314","journal-title":"mBio"},{"issue":"6","key":"12537_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1084\/jem.110.6.853","volume":"110","author":"EH Freimer","year":"1959","unstructured":"Freimer EH, Krause RM, McCarty M (1959) Studies of L forms and protoplasts of group A streptococci. I. Isolation, growth, and bacteriologic characteristics. J Exp Med 110(6):853\u2013874","journal-title":"J Exp Med"},{"issue":"10","key":"12537_CR28","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2217\/fmb.12.97","volume":"7","author":"M Schmelcher","year":"2012","unstructured":"Schmelcher M, Donovan DM, Loessner MJ (2012) Bacteriophage endolysins as novel antimicrobials. Future Microbiol 7(10):1147\u20131171","journal-title":"Future Microbiol"},{"key":"12537_CR29","doi-asserted-by":"crossref","unstructured":"Tesema MY (2025) Outlooks of endolysins with innolysins therapeutic potentials against antimicrobial resistance. Discov Med 2(1): 188","DOI":"10.1007\/s44337-025-00424-4"},{"issue":"5","key":"12537_CR30","doi-asserted-by":"publisher","first-page":"e0151922","DOI":"10.1128\/aac.01519-22","volume":"67","author":"CW Euler","year":"2023","unstructured":"Euler CW et al (2023) PlyKp104, a Novel Phage Lysin for the Treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and Other Gram-Negative ESKAPE Pathogens. Antimicrob Agents Chemother 67(5):e0151922","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"12537_CR31","doi-asserted-by":"publisher","first-page":"2273567","DOI":"10.1080\/21505594.2023.2273567","volume":"14","author":"Z Guo","year":"2023","unstructured":"Guo Z, Liu M, Zhang D (2023) Potential of phage depolymerase for the treatment of bacterial biofilms. Virulence 14(1):2273567","journal-title":"Virulence"},{"issue":"7432","key":"12537_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nature11723","volume":"493","author":"J Bondy-Denomy","year":"2013","unstructured":"Bondy-Denomy J et al (2013) Bacteriophage genes that inactivate the CRISPR\/Cas bacterial immune system. Nature 493(7432):429\u2013432","journal-title":"Nature"},{"issue":"8024","key":"12537_CR33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41586-024-07642-3","volume":"632","author":"CN Trost","year":"2024","unstructured":"Trost CN et al (2024) An anti-CRISPR that pulls apart a CRISPR-Cas complex. Nature 632(8024):375\u2013382","journal-title":"Nature"},{"issue":"6","key":"12537_CR34","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.cell.2017.07.037","volume":"170","author":"LB Harrington","year":"2017","unstructured":"Harrington LB et al (2017) A Broad-Spectrum Inhibitor of CRISPR-Cas9. Cell 170(6):1224\u20131233e15","journal-title":"Cell"},{"issue":"7658","key":"12537_CR35","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature22377","volume":"546","author":"D Dong","year":"2017","unstructured":"Dong D et al (2017) Structural basis of CRISPR-SpyCas9 inhibition by an anti-CRISPR protein. Nature 546(7658):436\u2013439","journal-title":"Nature"},{"issue":"2","key":"12537_CR36","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1574-695X.2012.00977.x","volume":"65","author":"EM Ryan","year":"2012","unstructured":"Ryan EM et al (2012) Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med Microbiol 65(2):395\u2013398","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"9","key":"12537_CR37","doi-asserted-by":"publisher","first-page":"e1011602","DOI":"10.1371\/journal.ppat.1011602","volume":"19","author":"J Bulssico","year":"2023","unstructured":"Bulssico J et al (2023) Phage-antibiotic synergy: Cell filamentation is a key driver of successful phage predation. PLoS Pathog 19(9):e1011602","journal-title":"PLoS Pathog"},{"key":"12537_CR38","doi-asserted-by":"crossref","unstructured":"Supina BSI, Dennis JJ (2025) The Current Landscape of Phage-Antibiotic Synergistic (PAS) Interactions. Antibiot (Basel) 14(6): 545","DOI":"10.3390\/antibiotics14060545"},{"issue":"8","key":"12537_CR39","doi-asserted-by":"publisher","first-page":"109172","DOI":"10.1016\/j.celrep.2021.109172","volume":"35","author":"AM Al-Anany","year":"2021","unstructured":"Al-Anany AM, Fatima R, Hynes AP (2021) Temperate phage-antibiotic synergy eradicates bacteria through depletion of lysogens. Cell Rep 35(8):109172","journal-title":"Cell Rep"},{"issue":"Suppl 14","key":"12537_CR40","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/1841079b0","volume":"184","author":"N Otsuji","year":"1959","unstructured":"Otsuji N et al (1959) Induction of phage formation in the lysogenic Escherichia coli K-12 by mitomycin C. Nature 184(Suppl 14):1079\u20131080","journal-title":"Nature"},{"key":"12537_CR41","doi-asserted-by":"crossref","unstructured":"Tan D et al (2020) A Frameshift Mutation in wcaJ Associated with Phage Resistance in Klebsiella pneumoniae. Microorganisms 8(3): 378","DOI":"10.3390\/microorganisms8030378"},{"issue":"10","key":"12537_CR42","doi-asserted-by":"publisher","first-page":"e0139324","DOI":"10.1128\/mbio.01393-24","volume":"15","author":"K Qin","year":"2024","unstructured":"Qin K et al (2024) Phage-antibiotic synergy suppresses resistance emergence of Klebsiella pneumoniae by altering the evolutionary fitness. mBio 15(10):e0139324","journal-title":"mBio"},{"issue":"7057","key":"12537_CR43","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/nature04160","volume":"437","author":"CA Suttle","year":"2005","unstructured":"Suttle CA (2005) Viruses in the sea. Nature 437(7057):956\u2013961","journal-title":"Nature"},{"issue":"1","key":"12537_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41579-021-00602-y","volume":"20","author":"A Chevallereau","year":"2022","unstructured":"Chevallereau A et al (2022) Interactions between bacterial and phage communities in natural environments. Nat Rev Microbiol 20(1):49\u201362","journal-title":"Nat Rev Microbiol"},{"issue":"7617","key":"12537_CR45","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nature19094","volume":"536","author":"D Paez-Espino","year":"2016","unstructured":"Paez-Espino D et al (2016) Uncovering earth\u2019s virome. Nature 536(7617):425\u2013430","journal-title":"Nature"},{"issue":"5","key":"12537_CR46","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/bioinformatics\/btw711","volume":"33","author":"DA Russell","year":"2016","unstructured":"Russell DA, Hatfull GF (2016) PhagesDB: the actinobacteriophage database. Bioinformatics 33(5):784\u2013786","journal-title":"Bioinformatics"},{"issue":"1","key":"12537_CR47","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1038\/s41467-024-46585-1","volume":"15","author":"A Levrier","year":"2024","unstructured":"Levrier A et al (2024) PHEIGES: all-cell-free phage synthesis and selection from engineered genomes. Nat Commun 15(1):2223","journal-title":"Nat Commun"},{"key":"12537_CR48","doi-asserted-by":"publisher","first-page":"1000721","DOI":"10.3389\/fcimb.2022.1000721","volume":"12","author":"V Daubie","year":"2022","unstructured":"Daubie V et al (2022) Determination of phage susceptibility as a clinical diagnostic tool: A routine perspective. Front Cell Infect Microbiol 12:1000721","journal-title":"Front Cell Infect Microbiol"},{"key":"12537_CR49","doi-asserted-by":"publisher","first-page":"594369","DOI":"10.1155\/2011\/594369","volume":"2011","author":"MH Ly-Chatain","year":"2011","unstructured":"Ly-Chatain MH et al (2011) Direct Quantitative Detection and Identification of Lactococcal Bacteriophages from Milk and Whey by Real-Time PCR: Application for the Detection of Lactococcal Bacteriophages in Goat\u2019s Raw Milk Whey in France. Int J Microbiol 2011:594369","journal-title":"Int J Microbiol"},{"issue":"7517","key":"12537_CR50","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature13459","volume":"513","author":"L Deng","year":"2014","unstructured":"Deng L et al (2014) Viral tagging reveals discrete populations in Synechococcus viral genome sequence space. Nature 513(7517):242\u2013245","journal-title":"Nature"},{"issue":"1","key":"12537_CR51","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1038\/s41467-024-49710-2","volume":"15","author":"F Bayat","year":"2024","unstructured":"Bayat F et al (2024) High throughput platform technology for rapid target identification in personalized phage therapy. Nat Commun 15(1):5626","journal-title":"Nat Commun"},{"issue":"1","key":"12537_CR52","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/microorganisms10010149","volume":"10","author":"CJ Versoza","year":"2022","unstructured":"Versoza CJ, Pfeifer SP (2022) Computational prediction of bacteriophage host ranges. Microorganisms 10(1):149","journal-title":"Microorganisms"},{"issue":"1","key":"12537_CR53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/nar\/gkw1002","volume":"45","author":"NA Ahlgren","year":"2017","unstructured":"Ahlgren NA et al (2017) Alignment-free d2* oligonucleotide frequency dissimilarity measure improves prediction of hosts from metagenomically-derived viral sequences. Nucleic Acids Res 45(1):39\u201353","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"12537_CR54","doi-asserted-by":"publisher","first-page":"e000421","DOI":"10.1128\/mmbr.00004-21","volume":"86","author":"JS Andrade-Mart\u00ednez","year":"2022","unstructured":"Andrade-Mart\u00ednez JS et al (2022) Computational tools for the analysis of uncultivated phage genomes. Microbiol Mol Biol Rev 86(2):e000421","journal-title":"Microbiol Mol Biol Rev"},{"issue":"11","key":"12537_CR55","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1038\/ismej.2015.48","volume":"9","author":"JM Labont\u00e9","year":"2015","unstructured":"Labont\u00e9 JM et al (2015) Single-cell genomics-based analysis of virus-host interactions in marine surface bacterioplankton. ISME J 9(11):2386\u20132399","journal-title":"ISME J"},{"issue":"7","key":"12537_CR56","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3390\/v14071490","volume":"14","author":"T Glonti","year":"2022","unstructured":"Glonti T, Pirnay JP (2022) In vitro techniques and measurements of phage characteristics that are important for phage therapy success. Viruses 14(7):1490","journal-title":"Viruses"},{"key":"12537_CR57","doi-asserted-by":"publisher","first-page":"259456","DOI":"10.1155\/2009\/259456","volume":"2009","author":"LRP Amorim","year":"2009","unstructured":"Amorim LRP et al (2009) Application of an impedimetric technique for the detection of lytic infection of salmonella spp. by specific phages. Int J Microbiol 2009:259456","journal-title":"Int J Microbiol"},{"key":"12537_CR58","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3389\/fmicb.2019.01674","volume":"10","author":"V Hietala","year":"2019","unstructured":"Hietala V et al (2019) The removal of endo- and enterotoxins from bacteriophage preparations. Front Microbiol 10:1674","journal-title":"Front Microbiol"},{"key":"12537_CR59","doi-asserted-by":"publisher","first-page":"465890","DOI":"10.1016\/j.chroma.2025.465890","volume":"1749","author":"JPP Saavedra","year":"2025","unstructured":"Saavedra JPP et al (2025) Scalable purification of bacteriophages preparations. J Chromatogr A 1749:465890","journal-title":"J Chromatogr A"},{"issue":"9","key":"12537_CR60","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/s41596-020-0346-0","volume":"15","author":"T Luong","year":"2020","unstructured":"Luong T et al (2020) Standardized bacteriophage purification for personalized phage therapy. Nat Protoc 15(9):2867\u20132890","journal-title":"Nat Protoc"},{"key":"12537_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.trsl.2020.03.010","volume":"220","author":"RYK Chang","year":"2020","unstructured":"Chang RYK et al (2020) Topical application of bacteriophages for treatment of wound infections. Transl Res 220:153\u2013166","journal-title":"Transl Res"},{"issue":"8","key":"12537_CR62","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/pharmaceutics13081162","volume":"13","author":"W Yan","year":"2021","unstructured":"Yan W et al (2021) The influence of formulation components and environmental humidity on spray-dried phage powders for treatment of respiratory infections caused by acinetobacter baumannii. Pharmaceutics 13(8):1162","journal-title":"Pharmaceutics"},{"key":"12537_CR63","doi-asserted-by":"publisher","first-page":"118601","DOI":"10.1016\/j.ijpharm.2019.118601","volume":"569","author":"NB Carrigy","year":"2019","unstructured":"Carrigy NB et al (2019) Spray-dried anti-campylobacter bacteriophage CP30A powder suitable for global distribution without cold chain infrastructure. Int J Pharm 569:118601","journal-title":"Int J Pharm"},{"key":"12537_CR64","doi-asserted-by":"publisher","first-page":"125602","DOI":"10.1016\/j.ijpharm.2025.125602","volume":"676","author":"V Pathak","year":"2025","unstructured":"Pathak V, Qu L, Zhou Q (2025) Powder aerosol formulation of pseudomonas aeruginosa bacteriophage for pulmonary delivery. Int J Pharm 676:125602","journal-title":"Int J Pharm"},{"key":"12537_CR65","doi-asserted-by":"crossref","unstructured":"Kaneko T, Nakatsuka K, Tsuneda S (2025) Phage cocktails: State-of-the-art technologies and strategies for effective design. FEMS Microbiol Rev fuaf061","DOI":"10.1093\/femsre\/fuaf061"},{"issue":"1","key":"12537_CR66","doi-asserted-by":"publisher","first-page":"9987","DOI":"10.1038\/s41467-024-53994-9","volume":"15","author":"MK Kim","year":"2024","unstructured":"Kim MK et al (2024) A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections. Nat Commun 15(1):9987","journal-title":"Nat Commun"},{"issue":"7","key":"12537_CR67","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3390\/antibiotics9070377","volume":"9","author":"CA Duplessis","year":"2020","unstructured":"Duplessis CA, Biswas B (2020) A review of topical phage therapy for chronically infected wounds and preparations for a randomized adaptive clinical trial evaluating topical phage therapy in chronically infected diabetic foot ulcers. Antibiot (Basel) 9(7):377","journal-title":"Antibiot (Basel)"},{"key":"12537_CR68","doi-asserted-by":"crossref","unstructured":"Johri AV et al (2021) Case report: Chronic bacterial prostatitis treated with phage therapy after multiple failed antibiotic treatments. Front Pharmacol 12: 692614","DOI":"10.3389\/fphar.2021.692614"},{"issue":"Suppl 2","key":"12537_CR69","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/jpids\/piac052","volume":"11","author":"AC Blanchard","year":"2022","unstructured":"Blanchard AC, Waters VJ (2022) Opportunistic pathogens in cystic fibrosis: Epidemiology and pathogenesis of lung infection. J Pediatr Infect Dis Soc 11(Suppl 2):S3\u2013S12","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"1","key":"12537_CR70","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41598-018-37636-x","volume":"9","author":"M Cafora","year":"2019","unstructured":"Cafora M et al (2019) Phage therapy against pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model. Sci Rep 9(1):1527","journal-title":"Sci Rep"},{"issue":"15","key":"12537_CR71","doi-asserted-by":"publisher","first-page":"8321","DOI":"10.3390\/ijms25158321","volume":"25","author":"M Cocorullo","year":"2024","unstructured":"Cocorullo M, Stelitano G, Chiarelli LR (2024) Phage therapy: An alternative approach to combating multidrug-resistant bacterial infections in cystic fibrosis. Int J Mol Sci 25(15):8321","journal-title":"Int J Mol Sci"},{"key":"12537_CR72","doi-asserted-by":"publisher","first-page":"120508","DOI":"10.1016\/j.ijpharm.2021.120508","volume":"602","author":"W Yan","year":"2021","unstructured":"Yan W et al (2021) Development of thermosensitive hydrogel wound dressing containing acinetobacter baumannii phage against wound infections. Int J Pharm 602:120508","journal-title":"Int J Pharm"},{"issue":"6","key":"12537_CR73","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1128\/AAC.01028-06","volume":"51","author":"CS McVay","year":"2007","unstructured":"McVay CS, Vel\u00e1squez M, Fralick JA (2007) Phage therapy of pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51(6):1934\u20131938","journal-title":"Antimicrob Agents Chemother"},{"key":"12537_CR74","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.micpath.2016.08.001","volume":"99","author":"P Chadha","year":"2016","unstructured":"Chadha P, Katare OP, Chhibber S (2016) In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB\/c mice. Microb Pathog 99:68\u201377","journal-title":"Microb Pathog"},{"issue":"1","key":"12537_CR75","doi-asserted-by":"publisher","first-page":"46151","DOI":"10.1038\/srep46151","volume":"7","author":"SI Green","year":"2017","unstructured":"Green SI et al (2017) Bacteriophages from ExPEC reservoirs kill pandemic multidrug-resistant strains of clonal group ST131 in animal models of bacteremia. Sci Rep 7(1):46151","journal-title":"Sci Rep"},{"issue":"6","key":"12537_CR76","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.micinf.2014.02.011","volume":"16","author":"I Takemura-Uchiyama","year":"2014","unstructured":"Takemura-Uchiyama I et al (2014) Experimental phage therapy against lethal lung-derived septicemia caused by staphylococcus aureus in mice. Microbes Infect 16(6):512\u2013517","journal-title":"Microbes Infect"},{"issue":"10","key":"12537_CR77","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/j.2042-7158.2011.01324.x","volume":"63","author":"EM Ryan","year":"2011","unstructured":"Ryan EM et al (2011) Recent advances in bacteriophage therapy: How delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol 63(10):1253\u20131264","journal-title":"J Pharm Pharmacol"},{"issue":"9","key":"12537_CR78","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/microorganisms8091420","volume":"8","author":"B Guti\u00e9rrez","year":"2020","unstructured":"Guti\u00e9rrez B, Domingo-Calap P (2020) Phage therapy in gastrointestinal diseases. Microorganisms 8(9):1420","journal-title":"Microorganisms"},{"key":"12537_CR79","doi-asserted-by":"publisher","first-page":"106830","DOI":"10.1016\/j.foodcont.2019.106830","volume":"108","author":"C Zhou","year":"2020","unstructured":"Zhou C et al (2020) Broad host range phage vB-LmoM-SH3-3 reduces the risk of listeria contamination in two types of ready-to-eat food. Food Control 108:106830","journal-title":"Food Control"},{"issue":"6","key":"12537_CR80","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.cmi.2023.01.021","volume":"29","author":"SC Nang","year":"2023","unstructured":"Nang SC et al (2023) Pharmacokinetics\/pharmacodynamics of phage therapy: a major hurdle to clinical translation. Clin Microbiol Infect 29(6):702\u2013709","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"12537_CR81","doi-asserted-by":"publisher","first-page":"107705","DOI":"10.1016\/j.ijantimicag.2025.107705","volume":"67","author":"AT Nguyen","year":"2026","unstructured":"Nguyen AT et al (2026) Pharmacokinetics and pharmacodynamics of bacteriophage therapy: A scoping review. Int J Antimicrob Agents 67(3):107705","journal-title":"Int J Antimicrob Agents"},{"key":"12537_CR82","doi-asserted-by":"crossref","unstructured":"Oechslin F (2018) Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy. Viruses 10(7): 351","DOI":"10.3390\/v10070351"},{"issue":"4","key":"12537_CR83","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/v11040343","volume":"11","author":"S McCallin","year":"2019","unstructured":"McCallin S et al (2019) Current state of compassionate phage therapy. Viruses 11(4):343","journal-title":"Viruses"},{"issue":"1","key":"12537_CR84","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1080\/22221751.2021.1902754","volume":"10","author":"N Wu","year":"2021","unstructured":"Wu N et al (2021) Pre-optimized phage therapy on secondary acinetobacter baumannii infection in four critical COVID-19 patients. Emerg Microbes Infect 10(1):612\u2013618","journal-title":"Emerg Microbes Infect"},{"issue":"5","key":"12537_CR85","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/antibiotics9050232","volume":"9","author":"E Rubalskii","year":"2020","unstructured":"Rubalskii E et al (2020) Bacteriophage therapy for critical infections related to cardiothoracic surgery. Antibiot (Basel) 9(5):232","journal-title":"Antibiot (Basel)"},{"issue":"5","key":"12537_CR86","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41591-025-03678-8","volume":"31","author":"BK Chan","year":"2025","unstructured":"Chan BK et al (2025) Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant pseudomonas aeruginosa in cystic fibrosis. Nat Med 31(5):1494\u20131501","journal-title":"Nat Med"},{"issue":"9","key":"12537_CR87","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.medj.2023.07.002","volume":"4","author":"H Onallah","year":"2023","unstructured":"Onallah H et al (2023) Refractory pseudomonas aeruginosa infections treated with phage PASA16: A compassionate use case series. Med 4(9):600\u2013611e4","journal-title":"Med"},{"issue":"2","key":"12537_CR88","first-page":"175","volume":"35","author":"M Cis\u0142o","year":"1987","unstructured":"Cis\u0142o M et al (1987) Bacteriophage treatment of suppurative skin infections. Arch Immunol Ther Exp (Warsz) 35(2):175\u2013183","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"1","key":"12537_CR89","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","volume":"19","author":"P Jault","year":"2019","unstructured":"Jault P et al (2019) Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1\/2 trial. Lancet Infect Dis 19(1):35\u201345","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"12537_CR90","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/cid\/ciad335","volume":"77","author":"SI Green","year":"2023","unstructured":"Green SI et al (2023) A retrospective, observational study of 12 cases of expanded-access customized phage therapy: Production, characteristics, and clinical outcomes. Clin Infect Dis 77(8):1079\u20131091","journal-title":"Clin Infect Dis"},{"issue":"6","key":"12537_CR91","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","volume":"9","author":"JP Pirnay","year":"2024","unstructured":"Pirnay JP et al (2024) Personalized bacteriophage therapy outcomes for 100 consecutive cases: A multicentre, multinational, retrospective observational study. Nat Microbiol 9(6):1434\u20131453","journal-title":"Nat Microbiol"},{"issue":"8","key":"12537_CR92","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/ph18081115","volume":"18","author":"SK Niazi","year":"2025","unstructured":"Niazi SK (2025) Bacteriophage therapy: Discovery, development, and FDA approval pathways. Pharmaceuticals 18(8):1115","journal-title":"Pharmaceuticals"},{"issue":"4","key":"12537_CR93","doi-asserted-by":"publisher","first-page":"e01728","DOI":"10.1128\/aac.01728-23","volume":"68","author":"S Aslam","year":"2024","unstructured":"Aslam S et al (2024) Pseudomonas aeruginosa ventricular assist device infections: Findings from ineffective phage therapies in five cases. Antimicrob Agents Chemother 68(4):e01728\u2013e01723","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"12537_CR94","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S1473-3099(20)30330-3","volume":"21","author":"L Leitner","year":"2021","unstructured":"Leitner L et al (2021) Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: A randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis 21(3):427\u2013436","journal-title":"Lancet Infect Dis"},{"key":"12537_CR95","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ebiom.2015.12.023","volume":"4","author":"SA Sarker","year":"2016","unstructured":"Sarker SA et al (2016) Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: A randomized trial in children from bangladesh. EBioMedicine 4:124\u2013137","journal-title":"EBioMedicine"},{"key":"12537_CR96","doi-asserted-by":"publisher","first-page":"104486","DOI":"10.1016\/j.jddst.2023.104486","volume":"84","author":"HR Samaee","year":"2023","unstructured":"Samaee HR et al (2023) Inhalation phage therapy as a new approach to preventing secondary bacterial pneumonia in patients with moderate to severe COVID-19: A double-blind clinical trial study. J Drug Deliv Sci Technol 84:104486","journal-title":"J Drug Deliv Sci Technol"},{"issue":"6","key":"12537_CR97","first-page":"547","volume":"48","author":"B Weber-Dabrowska","year":"2000","unstructured":"Weber-Dabrowska B, Mulczyk M, G\u00f3rski A (2000) Bacteriophage therapy of bacterial infections: An update of our institute\u2019s experience. Arch Immunol Ther Exp (Warsz) 48(6):547\u2013551","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"12537_CR98","doi-asserted-by":"publisher","first-page":"1611857","DOI":"10.3389\/fcimb.2025.1611857","volume":"15","author":"MB Doud","year":"2025","unstructured":"Doud MB, Robertson JM, Strathdee SA (2025) Optimizing phage therapy with artificial intelligence: a perspective. Front Cell Infect Microbiol 15:1611857","journal-title":"Front Cell Infect Microbiol"},{"key":"12537_CR99","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-981-13-7709-9_11","volume-title":"Therapeutic Enzymes: Function and Clinical Implications","author":"D Dams","year":"2019","unstructured":"Dams D, Briers Y, Enzybiotics (2019) Enzyme-Based Antibacterials as Therapeutics. In: Labrou N (ed) Therapeutic Enzymes: Function and Clinical Implications. Springer Singapore, Singapore, pp 233\u2013253"},{"key":"12537_CR100","doi-asserted-by":"publisher","first-page":"110559","DOI":"10.1016\/j.virol.2025.110559","volume":"609","author":"MKP Silva","year":"2025","unstructured":"Silva MKP et al (2025) Exploring deep learning in phage discovery and characterization. Virology 609:110559","journal-title":"Virology"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12537-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12537-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12537-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:02:19Z","timestamp":1791298939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12537-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12537"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12537-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The co-first authorship and equal contribution statement has been added.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"<b>Conflicts of interest<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1345"}}